Westchester Capital Management Inc. lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 0.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,884 shares of the medical instruments supplier’s stock after selling 60 shares during the quarter. Becton Dickinson and accounts for 4.3% of Westchester Capital Management Inc.’s portfolio, making the stock its 10th largest position. Westchester Capital Management Inc.’s holdings in Becton Dickinson and were worth $10,848,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently modified their holdings of BDX. TRUE Private Wealth Advisors purchased a new stake in Becton Dickinson and in the second quarter worth approximately $25,000. Allworth Financial LP boosted its holdings in Becton Dickinson and by 386.4% in the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 85 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in Becton Dickinson and in the 3rd quarter valued at $27,000. Hexavest Inc. bought a new stake in Becton Dickinson and in the 2nd quarter valued at $28,000. Finally, Lipe & Dalton bought a new stake in Becton Dickinson and in the 2nd quarter valued at $28,000. Institutional investors own 84.29% of the company’s stock.
In other Becton Dickinson and news, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total value of $393,761.12. Following the completion of the transaction, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the transaction, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 32,174 shares of company stock valued at $8,354,013 over the last three months. Corporate insiders own 0.12% of the company’s stock.
A number of brokerages have issued reports on BDX. Piper Jaffray Companies reduced their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Co reduced their price target on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $266.09.
Shares of NYSE:BDX traded up $0.22 on Friday, reaching $244.79. The company’s stock had a trading volume of 1,479,428 shares, compared to its average volume of 1,173,922. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $264.74. The company has a market cap of $66.59 billion, a P/E ratio of 20.96, a PEG ratio of 1.62 and a beta of 1.09. The company has a 50-day simple moving average of $251.93 and a 200 day simple moving average of $246.89. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The business had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same period last year, the company posted $2.93 EPS. The business’s revenue was up 4.1% on a year-over-year basis. On average, equities research analysts forecast that Becton Dickinson and Co will post 12.58 EPS for the current fiscal year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: How Does the Quiet Period Work?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.